Bright Minds Biosciences to Present at Upcoming Conferences




Bright Minds Biosciences to Present at Upcoming Conferences

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) — Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:

The live and archived webcast for the Guggenheim event will be accessible from the Company’s website at https://brightmindsbio.com/investors/ under Events and Presentation. The replay of the webcast will be accessible for 60 days.

Grant of Equity Incentive Awards

The Company has granted stock options (the “Options”) to certain directors, officers and consultants of the Company to purchase an aggregate 43,000 common shares (the “Shares”) in the capital of the Company pursuant to the Company’s share option plan. The Options are exercisable at an exercise price of US$54.47 per Share for a period of five (5) years from the date of grant. The Options are subject to vesting periods over the course of the term of the Options.

About Bright Minds Biosciences

Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients’ lives.

Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

Contact Information

Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com
Website: www.brightmindsbio.com

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.
The securities of the Company referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.

BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)




BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) — BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced two poster presentations featuring BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction, at the San Antonio Breast Cancer Symposium (SABCS) being held December 9-12, 2025, in San Antonio, Texas. The abstracts released today can be found on the SABCS website here.

Late Breaking Pre-clinical Poster Details:

• Title: BBO-10203, a first-in-class breaker of the RAS:PI3Kα interaction, inhibits tumor growth alone and in combination with fulvestrant or ribociclib in breast cancer models without inducing hyperglycemia
• Presentation Number: PS2-12-06
• Abstract Number: 3568
• Session Date/Time: Wednesday, December 10, from 5:00 p.m. – 6:30 p.m. CT
• Presenter: Kerstin Sinkevicius, PhD, Vice President, Pharmacology, BBOT

Trials in Progress Poster Details:

• Title: BREAKER-101: a phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-10203 in patients with advanced solid tumors
• Presentation Number: PS5-07-06
• Abstract Number: 203
• Session Date/Time: Friday, December 12, from 12:30 p.m. – 2:00 p.m. CT
• Presenter: Andreas Varkaris, MD, PhD, Attending Physician and Investigator, Massachusetts General Hospital

About BBO-10203
BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Kα, resulting in the inhibition of RAS-driven PI3Kα-AKT signaling in tumors without the risk of hyperglycemia. This novel mechanism of action makes BBO-10203 agnostic to the mutational status of either RAS or PI3Kα providing the potential to treat tumors driven by KRAS or PI3Kα mutations, the two most mutated oncogenes in human cancer. BBO-10203 is being evaluated in the Phase 1 BREAKER-101 trial for patients with HER2+ amplified or HR+/HER2- breast cancer, and KRAS mutant colorectal or non-small cell lung cancer.

About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

BBOT Contacts:

Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com

Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com

Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025




Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025

Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025

Mont-Saint-Guibert, Belgium – Thursday, October 30, 2025, 10:10pm CET / 5:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2025 on Thursday, November 13, 2025. Company management will host a conference call to discuss financial results that day beginning 10:30pm CET / 4:30pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah’s Q3 2025 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah’s Q3 2025 Earnings Call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and U.S. FDA approval of a Premarket Approval application.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

FORWARD-LOOKING STATEMENTS
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio system; the Company’s commercialization strategy and entrance to the U.S. market; the Company’s intellectual property portfolio; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, or adverse litigation outcomes can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Investor and Media Contact:
Rémi Renard
Chief Investor Relations and Corporate Communication Officer
IR@nyxoah.com

Attachment

• ENGLISH_Q3 Earnings Call Announcement_FINAL

MEDIROM MOTHER Labs Inc. Receives Capital Investment from Internal Investors




MEDIROM MOTHER Labs Inc. Receives Capital Investment from Internal Investors

Completion of Private Placement of New Shares as Part of Series A Round Valued at ¥9 Billion

TOKYO, Oct. 30, 2025 (GLOBE NEWSWIRE) — MEDIROM MOTHER Labs Co., Ltd. (Headquarters: Minato-ku, Tokyo; President and CEO: Yoshio Uekusa; hereinafter “MEDIROM MOTHER Labs”), a subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), has completed a private placement of new shares to its President and CEO, Yoshio Uekusa, and Director, Ryo Saito. This transaction is part of the previously announced Series A round, valued at ¥9 billion.

︎Background of Implementation
MEDIROM MOTHER Labs, as the health tech division of the Medirom Group, has been advancing the implementation of specific health guidance utilizing the healthcare app “Lav” and the development and sales of the wearable device “MOTHER Bracelet”. To further expand our business going forward, we aim to enhance swift decision-making and a field-driven management structure. By having the management team itself become investors, we seek to further increase business responsibility and growth motivation.

︎Future Outlook
With the completion of this capital increase, MEDIROM MOTHER Labs will further strengthen its capital base and accelerate the development of upgraded versions of the wearable device “MOTHER Bracelet” and the establishment of systems for launching new products into the market. As the Medirom Group, we will realize the delivery of new value in the healthcare and wellness field and drive sustainable growth both domestically and internationally.

ABOUT MEDIROM MOTHER Labs Inc.

A subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), focuses on the health- tech sector. The company’s core activities include the ‘Specific Health Guidance Program’ offered through the ‘Lav’ health application and development and sales of the 24/7 recharge-free MOTHER Bracelet smart tracker. By leveraging the features of the recharge-free MOTHER Bracelet, MOTHER Labs offers customizable health management solutions across diverse sectors, including caregiving, logistics, manufacturing, etc.

︎MEDIROM Healthcare Technologies Inc.

MEDIROM Healthcare Technologies Inc.
NASDAQ Symbol: MRM
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan
Web: https://medirom.co.jp/en
Contact: ir@medirom.co.jp

Forward-Looking Statements Regarding MEDIROM 
Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about MEDIROM’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to MEDIROM’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause MEDIROM’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond MEDIROM’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects MEDIROM’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MEDIROM’s operations, results of operations, growth strategy and liquidity. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release include:

• MEDIROM’s ability to achieve its development goals for its business and execute and evolve its growth strategies, priorities and initiatives;
• changes in Japanese and global economic conditions and financial markets, including their effects on MEDIROM’s expansion in Japan and certain overseas markets;
• MEDIROM’s ability to achieve and sustain profitability in its Digital Preventative Healthcare Segment;
• the fluctuation of foreign exchange rates, which affects MEDIROM’s expenses and liabilities payable in foreign currencies;
• MEDIROM’s ability to maintain and enhance the value of its brands and to enforce and maintain its trademarks and protect its other intellectual property;
• MEDIROM’s ability to raise additional capital on acceptable terms or at all;
• MEDIROM’s level of indebtedness and potential restrictions on MEDIROM under MEDIROM’s debt instruments;
• changes in consumer preferences and MEDIROM’s competitive environment; 
• MEDIROM’s ability to respond to natural disasters, such as earthquakes and tsunamis, and to global pandemics, such as COVID-19; and
• the regulatory environment in which MEDIROM operates.

More information on these risks and other potential factors that could affect MEDIROM’s business, reputation, results of operations, financial condition, and stock price is included in MEDIROM’s filings with the Securities and Exchange Commission (the “SEC”), including in the “Risk Factors” and “Operating and Financial Review and Prospects” sections of MEDIROM’s most recently filed periodic report on Form 20-F and subsequent filings, which are available on the SEC website at www.sec.gov. MEDIROM assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/88366bf6-f544-42a6-883a-44e4a00ce143

https://www.globenewswire.com/NewsRoom/AttachmentNg/6f209e52-40b4-4ad3-838c-146ee389b046

Rapid Micro Biosystems to Participate in the Stifel 2025 Healthcare Conference




Rapid Micro Biosystems to Participate in the Stifel 2025 Healthcare Conference

LEXINGTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Stifel 2025 Healthcare Conference in New York, NY.

Company management is scheduled to participate in a 30-minute question-and-answer session with the host analyst on Tuesday, November 11, 2025, at 11:20 a.m. ET. A live webcast will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay after the event.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.

CONTACT: Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
mbeaulieu@rapidmicrobio.com

Media Contact:
media@rapidmicrobio.com

Corbus Pharmaceuticals Announces Proposed Public Offering




Corbus Pharmaceuticals Announces Proposed Public Offering

NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten registered public offering. All of the securities in the offering are to be sold by Corbus. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Corbus intends to use the net proceeds of the proposed underwritten offering to fund the clinical development of its pipeline and for working capital and other general corporate purposes.

Jefferies LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering. Corbus intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) and became effective on March 20, 2024. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offering will be made only by means of a prospectus, copies of which may be obtained, when available, at the SEC’s website at www.sec.gov, or by request at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts.

Forward-Looking Statements

Statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements about Corbus’ expectations regarding the completion, timing and size of its public offering and the anticipated use of proceeds therefrom. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties associated with Corbus’ business and finances in general, including the risks and uncertainties in the section captioned “Risk Factors” in the preliminary prospectus supplement related to the public offering that will be filed with the SEC and the Company’s most recently filed Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q. There can be no assurances that we will be able to complete the proposed offering on the anticipated terms, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Corbus undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Corbus Pharmaceuticals Contacts: 

Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors




DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

Châtillon, France, October 30, 2025

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the “Board”), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by the Company’s shareholders at the next annual meeting of shareholders. Dr. Lee will also serve as a member of the Compensation Committee of the Board. With this addition, the Company’s Board comprises ten directors.

“We are pleased to welcome Philina Lee as a new independent director to the Board,” said Michel de Rosen, Chairman of the Board. “Philina’s extensive experience building successful biopharmaceutical organizations and commercializing pharmaceutical products will add tremendous value as the Company moves closer to potential commercialization.”

Dr. Lee joins DBV following a distinguished tenure at Blueprint Medicines where she progressed through increasingly senior roles, culminating in her leadership of the company’s commercial organization as Chief Commercial Officer, overseeing the successful launch and growth of AYVAKIT®. She previously was on the Board of Directors at Fusion Pharmaceuticals, where she served on both the Nomination and Governance Committee and the Research and Development Committee.

“I am honored to join DBV’s Board at such a pivotal time for the Company, as it continues to advance VIASKIN® Peanut for children and toddlers with peanut allergy,” said Dr. Lee. “I look forward to serving on the Compensation Committee and contributing to DBV’s growth and success.”

About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).

VIASKIN is a registered trademark of DBV Technologies.

Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com

Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com

Attachment

• PDF Version

Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025




Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025

SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present a trial-in-progress poster for the Phase 3 OPERA-02 trial at the 2025 San Antonio Breast Cancer Symposium (SABCS 2025) taking place December 9-12, 2025 in San Antonio, TX. The trial is evaluating palazestrant in combination with ribociclib in frontline estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.

Poster Presentation Details
Title: OPERA-02: a phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer
Abstract Number: 264
Presentation Number: PS5-12-18
Date/Time: Friday, December 12, 2025 from 12:30pm–2:00pm CT / 1:30pm–3:00pm ET

Additional information can be found on the SABCS website. A copy of the poster will be made available on the Publications page of Olema’s website in alignment with the SABCS 2025 embargo policy.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

About Palazestrant (OP-1250)
Palazestrant (OP-1250) is a novel, orally available small molecule with dual activity as both a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD). It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In clinical studies, palazestrant completely blocks ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer and has demonstrated anti-tumor efficacy along with attractive pharmacokinetics and exposure, favorable tolerability, central nervous system penetration, and combinability with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Palazestrant has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. It is being evaluated as a single agent in the ongoing pivotal Phase 3 clinical trial, OPERA-01 and in combination with ribociclib in the ongoing pivotal Phase 3 clinical trial, OPERA-02. Palazestrant is also being evaluated in multiple Phase 1/2 studies in combination with ribociclib, palbociclib, alpelisib, everolimus, and atirmociclib.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

Psychologie Berlin’s Dr. Dirk Stemper Announces New Book: The Vagus Nerve: Why You Don’t Need a Reset – Real Neuromodulation for Exhaustion, Trauma, and Long COVID




Psychologie Berlin’s Dr. Dirk Stemper Announces New Book: The Vagus Nerve: Why You Don’t Need a Reset – Real Neuromodulation for Exhaustion, Trauma, and Long COVID

New book reveals evidence-based approaches for nervous system dysfunction—debunking quick fixes and offering actionable strategies in neuromodulation, biofeedback, and trauma recovery.

Vagus Nerve—Science, Not Myth: Dr. Dirk Stemper Exposes Reset Myths and Offers Research-Based Solutions for Fatigue, Inflammation, and Long COVID

Berlin, Germany, Oct. 30, 2025 (GLOBE NEWSWIRE) —  Chronic fatigue, persistent inflammation, and long COVID symptoms drive millions to search for answers about the vagus nerve every month. Psychologie Berlin, alongside founder Dr. Dirk Stemper, internal medicine specialist and psychotherapist, releases “The Vagus Nerve: Why You Don’t Need a Reset – Real Neuromodulation for Exhaustion, Trauma, and Long COVID”, a new book that delivers science-driven clarity for health professionals and individuals struggling with exhaustion and chronic disease.

Science, Not Myth: Dr. Dirk Stemper’s new book, The Vagus Nerve, delivers evidence-based solutions for exhaustion, trauma, and long COVID—debunking wellness industry reset myths and revealing the real power of gentle neuromodulation.

Five Ws: Core Facts

– Who: Dr. Dirk Stemper, M.D., a German board-certified internal medicine specialist and practicing psychotherapist (20+ years clinical experience).

– What: Launch of an evidence-based book debunking vagus nerve “reset” myths and wellness industry misinformation.

– When: October 2025, global release in hardcover, paperback, audiobook and eBook formats.

– Where: Available worldwide on amazon.com, published by Psychologie Halensee.

– Why: To educate about real causes and solutions for nervous system dysfunction, chronic fatigue, dysautonomia, post-viral syndromes, and the value of neuromodulation.

 Key Takeaways

– Quick fixes and “vagus nerve resets” lack scientific support; Dr. Stemper details the real anatomy, function, and therapeutic interventions.

– Exhaustion, CPTSD, neurodiversity, and inflammation are explained as biopsychosocial patterns, not personal defects.

– Modern, gentle neuromodulation (transcutaneous stimulation, HRV biofeedback) emerges as a promising clinical approach, validated by peer-reviewed research.

– Readers gain actionable strategies without relying on pseudoscience or pricey gadgets.

 Expert Quote

“This book clarifies how nervous system support must be rooted in evidence, not hype. My goal is for patients and caregivers to see beyond the noise—toward compassionate, research-based care,” said Dr. Dirk Stemper.

FAQ

Q: Who should read this book? 

A: Patients, and caregivers dealing with chronic fatigue, inflammation, long COVID, trauma, or interest in biofeedback and neuromodulation therapies.

Q: What makes this book different from wellness guides? 

A: It dispels reset myths, avoids self-optimization culture, and provides clinically reviewed research and practical steps.

Q: Is the vagus nerve important for long COVID or CPTSD? 

A: Yes. The book describes how vagus nerve modulation influences inflammation, autonomic balance, and trauma recovery.

Q: What methods does Dr. Stemper endorse? 

A: Non-invasive, evidence-based neuromodulation: electrical, magnetic, or sensory stimulation and HRV biofeedback.

 Author Boilerplate

Dr. Dirk Stemper, is a board-certified internist and practicing psychotherapist specializing in trauma recovery and neurodiversity. With over two decades of clinical and research experience, he advocates for scientific rigor in integrative medicine.

Dr. Dirk Stemper, internal medicine specialist and psychotherapist, author of The Vagus Nerve—Science, Not Myth: Why You Don’t Need a Reset—dedicated to evidence-based solutions for exhaustion, trauma, and long COVID.

About Psychologie Berlin

Psychologie Berlin is a Berlin-based private practice focused on integrative mental health, offering evidence-based psychotherapy and medical consultation with specialization in trauma recovery, neurodiversity, and nervous system regulation. Bridging clinical psychology and internal medicine, the practice supports individuals facing chronic fatigue, post-viral conditions, and stress-related disorders with a biopsychosocial approach. Dr. Dirk Stemper is a doctor, psychotherapist, and coach based in Berlin. At Psychologie Berlin, he regularly publishes on health and societal issues (most recently with Orientations Press, 2025). 

Press inquiries

Psychologie Berlin
https://www.praxis-psychologie-berlin.de
Dr. Dirk Stemper
info@praxis-psychologie-berlin.de
‭+49 179 5911328‬
Kalckreuthstr. 16
10777 Berlin
c./o. AVATARAS Institut
Germany

Psychologie Berlin’s Dr. Dirk Stemper Announces New Book: The Vagus Nerve: Why You Don’t Need a Reset – Real Neuromodulation for Exhaustion, Trauma, and Long COVID




Psychologie Berlin’s Dr. Dirk Stemper Announces New Book: The Vagus Nerve: Why You Don’t Need a Reset – Real Neuromodulation for Exhaustion, Trauma, and Long COVID

New book reveals evidence-based approaches for nervous system dysfunction—debunking quick fixes and offering actionable strategies in neuromodulation, biofeedback, and trauma recovery.

Vagus Nerve—Science, Not Myth: Dr. Dirk Stemper Exposes Reset Myths and Offers Research-Based Solutions for Fatigue, Inflammation, and Long COVID

Berlin, Germany, Oct. 30, 2025 (GLOBE NEWSWIRE) —  Chronic fatigue, persistent inflammation, and long COVID symptoms drive millions to search for answers about the vagus nerve every month. Psychologie Berlin, alongside founder Dr. Dirk Stemper, internal medicine specialist and psychotherapist, releases “The Vagus Nerve: Why You Don’t Need a Reset – Real Neuromodulation for Exhaustion, Trauma, and Long COVID”, a new book that delivers science-driven clarity for health professionals and individuals struggling with exhaustion and chronic disease.

Science, Not Myth: Dr. Dirk Stemper’s new book, The Vagus Nerve, delivers evidence-based solutions for exhaustion, trauma, and long COVID—debunking wellness industry reset myths and revealing the real power of gentle neuromodulation.

Five Ws: Core Facts

– Who: Dr. Dirk Stemper, M.D., a German board-certified internal medicine specialist and practicing psychotherapist (20+ years clinical experience).

– What: Launch of an evidence-based book debunking vagus nerve “reset” myths and wellness industry misinformation.

– When: October 2025, global release in hardcover, paperback, audiobook and eBook formats.

– Where: Available worldwide on amazon.com, published by Psychologie Halensee.

– Why: To educate about real causes and solutions for nervous system dysfunction, chronic fatigue, dysautonomia, post-viral syndromes, and the value of neuromodulation.

 Key Takeaways

– Quick fixes and “vagus nerve resets” lack scientific support; Dr. Stemper details the real anatomy, function, and therapeutic interventions.

– Exhaustion, CPTSD, neurodiversity, and inflammation are explained as biopsychosocial patterns, not personal defects.

– Modern, gentle neuromodulation (transcutaneous stimulation, HRV biofeedback) emerges as a promising clinical approach, validated by peer-reviewed research.

– Readers gain actionable strategies without relying on pseudoscience or pricey gadgets.

 Expert Quote

“This book clarifies how nervous system support must be rooted in evidence, not hype. My goal is for patients and caregivers to see beyond the noise—toward compassionate, research-based care,” said Dr. Dirk Stemper.

FAQ

Q: Who should read this book? 

A: Patients, and caregivers dealing with chronic fatigue, inflammation, long COVID, trauma, or interest in biofeedback and neuromodulation therapies.

Q: What makes this book different from wellness guides? 

A: It dispels reset myths, avoids self-optimization culture, and provides clinically reviewed research and practical steps.

Q: Is the vagus nerve important for long COVID or CPTSD? 

A: Yes. The book describes how vagus nerve modulation influences inflammation, autonomic balance, and trauma recovery.

Q: What methods does Dr. Stemper endorse? 

A: Non-invasive, evidence-based neuromodulation: electrical, magnetic, or sensory stimulation and HRV biofeedback.

 Author Boilerplate

Dr. Dirk Stemper, is a board-certified internist and practicing psychotherapist specializing in trauma recovery and neurodiversity. With over two decades of clinical and research experience, he advocates for scientific rigor in integrative medicine.

Dr. Dirk Stemper, internal medicine specialist and psychotherapist, author of The Vagus Nerve—Science, Not Myth: Why You Don’t Need a Reset—dedicated to evidence-based solutions for exhaustion, trauma, and long COVID.

About Psychologie Berlin

Psychologie Berlin is a Berlin-based private practice focused on integrative mental health, offering evidence-based psychotherapy and medical consultation with specialization in trauma recovery, neurodiversity, and nervous system regulation. Bridging clinical psychology and internal medicine, the practice supports individuals facing chronic fatigue, post-viral conditions, and stress-related disorders with a biopsychosocial approach. Dr. Dirk Stemper is a doctor, psychotherapist, and coach based in Berlin. At Psychologie Berlin, he regularly publishes on health and societal issues (most recently with Orientations Press, 2025). 

Press inquiries

Psychologie Berlin
https://www.praxis-psychologie-berlin.de
Dr. Dirk Stemper
info@praxis-psychologie-berlin.de
‭+49 179 5911328‬
Kalckreuthstr. 16
10777 Berlin
c./o. AVATARAS Institut
Germany